Business Context and Reporting Period
This Form 8-K was filed by Akebia Therapeutics, Inc. on June 8, 2015, reporting a material event that occurred on the same date. The Company is a biopharmaceutical firm focused on developing treatments for anemia secondary to chronic kidney disease (CKD) in non-dialysis patients.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the execution of a contractual agreement.
Material Changes
On June 8, 2015, the Company entered into a Master Services Agreement with Quintiles, Inc., a contract research organization (CRO). This agreement supports the Company's planned Phase 3 clinical studies for its lead product candidate, AKB-6548.
- Services: The CRO will provide clinical trial services, statistical analysis, data processing, data management, and project management via work orders.
- Term: The agreement lasts through June 8, 2018, or until the completion of all services under executed work orders, whichever is later.
- Intellectual Property: The Company retains exclusive rights to all inventions, discoveries, and data arising from the services, with the CRO assigning related patent rights to the Company.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or specific risk factors beyond the standard contractual provisions. The agreement includes customary representations, warranties, covenants, and confidentiality provisions. The full text of the Master Services Agreement is referenced as an exhibit to be filed in the next quarterly report on Form 10-Q.
Investor Verification Checklist
- Verify the specific budget and payment schedule details in the work orders to be executed under the Master Services Agreement.
- Review the full Master Services Agreement when filed as an exhibit to the next Form 10-Q for detailed liability and termination clauses.
- Monitor the progress of the Phase 3 clinical studies for AKB-6548 to assess the utilization of the CRO services.
- Confirm the Company's cash position in upcoming filings to ensure sufficient liquidity to fund the fees and expenses associated with this agreement.